Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
381-400 of 1,738 trials

Ovarian Cancer: 68Ga-FAPI PET/CT Imaging Study

We are comparing a new imaging technique to standard methods for diagnosing and monitoring ovarian cancer. This study aims to see if the new method improves patient management and safety.

Ovarian Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyOtolaryngology

Melanoma: Ipilimumab and Nivolumab Combination

We are testing a new treatment using two immunotherapy drugs for patients with high-risk stage II melanoma. The goal is to see if this combination can improve outcomes before surgery.

Stage II Melanoma6-12 monthsEfficacy phase (II)DermatologyOncology

Type 2 Diabetes: Semaglutide for Bone Health

We are investigating whether oral Semaglutide can improve bone formation and strength in men and women with type 2 diabetes. This study focuses on those with normal or low bone mass.

Type 2 Diabetes1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementDiabetologyEndocrinologyRheumatology

Diabetes Foot Ulcers: Mesenchymal Stem Cells Study

We are exploring whether mesenchymal stem cells can help heal foot ulcers in people with diabetes. This early study aims to assess the safety and potential benefits of this treatment.

Diabetic Foot Ulcer>2 yearsSafety phase (I)Efficacy phase (II)DermatologyDiabetology

Basal Cell Carcinoma: Tirbanibulin (Klisyri®) Treatment Study

We are studying the effectiveness and safety of Tirbanibulin (Klisyri®) for treating superficial basal cell carcinoma. The trial will also look at how well patients tolerate the treatment and their overall satisfaction.

Superficial Basal Cell Carcinoma≤3 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesDermatology

Severe Systemic Sclerosis: Stem Cell Treatment Study

We are investigating the safety of a new stem cell therapy for people with severe systemic sclerosis. The study aims to see if this treatment can improve skin and lung function.

Systemic Sclerosis>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesInternal MedicineRheumatology

Severe Community-Acquired Pneumonia: AON-D21 Treatment Study

We are testing a new drug, AON-D21, as an additional treatment for patients with severe community-acquired pneumonia in intensive care. The study aims to assess its safety and effectiveness compared to a placebo.

Severe Community-Acquired Pneumonia≤3 monthsEfficacy phase (II)>20 visitsInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

High-Risk Aggressive B-Cell Lymphomas: R-Hyper-CVAD/R-MA Treatment

We are studying a new treatment approach for patients with high-risk aggressive B-cell lymphomas to see if it is effective and safe. This trial aims to improve outcomes for those facing this serious condition.

Lymphoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

HMB-001 for Glanzmann Thrombasthenia

We are investigating a new treatment to see if it is safe and can help reduce bleeding in people with Glanzmann Thrombasthenia. This study will also look at how the body processes the medication and its effects on quality of life.

Glanzmann's Disease1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematology

Myotonic Dystrophy Type 1: VX-670 Study

We are testing the safety and tolerability of a new drug, VX-670, in adults with myotonic dystrophy type 1. This study aims to understand how the drug works in the body and its potential benefits.

Myotonic DystrophySafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Hypertonic Lactate After Cardiac Arrest: The LATTE Trial

We are studying whether hypertonic sodium lactate can help reduce brain injury in comatose survivors of cardiac arrest. This trial will also look at its effects on recovery and safety.

Cardiac ArrestComaPost Cardiac Arrest Syndrome≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyNeurology

Follicular Lymphoma: Mosunetuzumab and Zanubrutinib Study

We are investigating a combination of two medications for patients with relapsed or refractory follicular lymphoma. The goal is to see if this treatment improves outcomes and safety compared to existing options.

Follicular Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematology

Ketamine for Depression and Alcohol Use Disorder

We are studying whether ketamine can help adults with depression and alcohol use disorder during their addiction treatment. The trial will also look at the safety of this treatment approach.

DepressionAlcohol Use Disorder6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemotePsychiatry

Achondroplasia: TransCon CNP Treatment for Infants

We are investigating the safety and growth effects of weekly injections of TransCon CNP in infants with achondroplasia. This study aims to understand how the treatment may help with growth and development.

Achondroplasia1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementEndocrinologyPediatrics

Gastric Cancer: Dostarlimab Immunotherapy Study

We are exploring a new treatment approach for patients with localized gastric cancer to see if delaying surgery while using Dostarlimab can be effective. The study aims to evaluate patient responses and safety over time.

Metastatic Gastric Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterologyOncology

Cerebral Amyloid Angiopathy: New Treatment Approaches

We are studying whether non-invasive vagus nerve stimulation and low-sodium oxybate can help clear amyloid-beta from the brain in patients with cerebral amyloid angiopathy. This research aims to improve understanding of potential treatments for this condition.

Cerebral Amyloid Angiopathy≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Efgartigimod PH20 SC for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to under 18 with generalized myasthenia gravis. The trial will help us understand the right dose and evaluate its safety and effects on daily life.

Myasthenia Gravis3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

GHB Use Disorder: Baclofen Treatment Study

We are testing whether adding baclofen can help reduce the need for GHB during detox for patients with GHB use disorder. This study aims to improve the detox process for those seeking recovery.

GHB Use DisorderEfficacy phase (II)No PlaceboStandard MedicinesPsychiatry

Neonatal OTC Deficiency: ECUR-506 Treatment Study

We are investigating a new treatment called ECUR-506 for boys under 9 months with neonatal onset OTC deficiency. The study will help us understand its safety and how well it works.

Ornithine Transcarbamylase Deficiency6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicinePediatrics

Diffuse Large B-cell Lymphoma: Rituximab and Golcadomide Study

We are testing a new combination treatment for older frail patients with Diffuse Large B-cell non-Hodgkin Lymphoma. This study aims to see if it can improve outcomes without traditional chemotherapy.

Diffuse Large B-cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyInternal Medicine